To Test or Not to Test?

Posted by Pranav Srivastava on Thu, Oct 01, 2015

Testing beyond BRCA in breast and ovarian cancers was the focus of a recent article in JAMA Oncology. The conclusion was:

In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone. Multigene testing in this setting is likely to alter near-term cancer risk assessment and management recommendations for mutation-affected individuals across a broad spectrum of cancer predisposition genes.


>
Read More